{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:45:04Z","timestamp":1793191504002,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40265-022-01725-z","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T05:02:57Z","timestamp":1655355777000},"page":"913-923","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Delafloxacin: A Review in Community-Acquired Pneumonia"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7831","authenticated-orcid":false,"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette N.","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"1725_CR1","unstructured":"European Respiratory Society. European lung white book. 2022. https:\/\/www.erswhitebook.org\/. Accessed 28 Apr 2022."},{"key":"1725_CR2","volume-title":"Community-acquired pneumonia","author":"StatPearls","year":"2022","unstructured":"StatPearls. Community-acquired pneumonia. Treasure Island: StatPearls Publishing; 2022."},{"issue":"7","key":"1725_CR3","doi-asserted-by":"publisher","first-page":"ofab063","DOI":"10.1093\/ofid\/ofab063","volume":"8","author":"V Gupta","year":"2021","unstructured":"Gupta V, Yu KC, Schranz J, et al. A multicenter evaluation of the US prevalence and regional variation in macrolide-resistant S. pneumoniae in ambulatory and hospitalized adult patients in the United States. Open Forum Infect Dis. 2021;8(7):ofab063.","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"1725_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s40261-020-00953-z","volume":"40","author":"R Sharma","year":"2020","unstructured":"Sharma R, Sandrock CE, Meehan J, et al. Community-acquired bacterial pneumonia\u2014changing epidemiology, resistance patterns, and newer antibiotics: spotlight on delafloxacin. Clin Drug Investig. 2020;40(10):947\u201360.","journal-title":"Clin Drug Investig"},{"key":"1725_CR5","unstructured":"Melinta Therapeutics. BAXDELA (delafloxacin): US prescribing information. 2021. https:\/\/dailymed.nlm.nih.gov\/. Accessed 28 Apr 2022."},{"key":"1725_CR6","unstructured":"European Medicines Agency. Quofenix (delafloxacin) 450 mg oral tablets and 300 mg powder for infusion: EU prescribing information. 2021. https:\/\/www.ema.europa.eu\/. Accessed 28 Apr 2022."},{"issue":"12","key":"1725_CR7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s40265-020-01358-0","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Delafloxacin: a review in acute bacterial skin and skin structure infections. Drugs. 2020;80(12):1247\u201358.","journal-title":"Drugs"},{"key":"1725_CR8","unstructured":"US Food and Drug Administration. Delafloxacin injection and oral products. 2020. https:\/\/www.fda.gov\/. Accessed 28 Apr 2022."},{"key":"1725_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijid.2020.06.018","volume":"97","author":"S McCurdy","year":"2020","unstructured":"McCurdy S, Nenninger A, Sheets A, et al. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): data from the delafloxacin phase 3 CABP trial. Int J Infect Dis. 2020;97:374\u20139.","journal-title":"Int J Infect Dis"},{"key":"1725_CR10","unstructured":"Data on file, Menarini Group, 2022."},{"issue":"3","key":"1725_CR11","doi-asserted-by":"publisher","first-page":"e01949","DOI":"10.1128\/AAC.01949-19","volume":"64","author":"S McCurdy","year":"2020","unstructured":"McCurdy S, Keedy K, Lawrence L, et al. Efficacy of delafloxacin versus moxifloxacin against bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): microbiology results from the delafloxacin phase 3 CABP trial. Antimicrob Agents Chemother. 2020;64(3):e01949-e2019.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"1725_CR12","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","volume":"47","author":"AM Nilius","year":"2003","unstructured":"Nilius AM, Shen LL, Hensey-Rudloff D, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother. 2003;47(10):3260\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1725_CR13","doi-asserted-by":"publisher","first-page":"dlab057","DOI":"10.1093\/jacamr\/dlab057","volume":"3","author":"SP McCurdy","year":"2021","unstructured":"McCurdy SP, Sheets AJ, Cammarata SK, et al. Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates from a phase III community-acquired bacterial pneumonia (CABP) trial. JAC Antimicrob Resist. 2021;3(2):dlab057.","journal-title":"JAC Antimicrob Resist."},{"issue":"12","key":"1725_CR14","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1093\/jac\/dks307","volume":"67","author":"JM Remy","year":"2012","unstructured":"Remy JM, Tow-Keogh CA, McConnell TS, et al. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother. 2012;67(12):2814\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"1725_CR15","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1093\/cid\/ciz787","volume":"70","author":"A Iregui","year":"2020","unstructured":"Iregui A, Khan Z, Malik S, et al. Emergence of delafloxacin-resistant Staphylococcus aureus in Brooklyn, New York. Clin Infect Dis. 2020;70(8):1758\u201360.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1725_CR16","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1093\/jac\/dkaa209","volume":"75","author":"LD Saravolatz","year":"2020","unstructured":"Saravolatz LD, Pawlak JM, Wegner C. Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid. J Antimicrob Chemother. 2020;75(9):2605\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"1725_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1128\/AAC.01201-10","volume":"55","author":"S Lemaire","year":"2011","unstructured":"Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55(2):649\u201358.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"1725_CR18","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.3390\/ijms22073384","volume":"22","author":"M Zajac","year":"2021","unstructured":"Zajac M, Dreano E, Edwards A, et al. Airway surface liquid pH regulation in airway epithelium current understandings and gaps in knowledge. Int J Mol Sci. 2021;22(7):3384.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1725_CR19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ijantimicag.2016.08.012","volume":"48","author":"AK Thabit","year":"2016","unstructured":"Thabit AK, Crandon JL, Nicolau DP. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. Int J Antimicrob Agents. 2016;48(5):535\u201341.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"1725_CR20","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1128\/AAC.00647-16","volume":"60","author":"AJ Lepak","year":"2016","unstructured":"Lepak AJ, Andes DR. In vivo pharmacodynamic target assessment of delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a murine lung infection model. Antimicrob Agents Chemother. 2016;60(8):4764\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"1725_CR21","doi-asserted-by":"publisher","first-page":"e01131","DOI":"10.1128\/AAC.01131-19","volume":"63","author":"M Zhao","year":"2019","unstructured":"Zhao M, Lepak AJ, Marchillo K, et al. In vivo pharmacodynamic target determination for delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the neutropenic murine pneumonia model. Antimicrob Agents Chemother. 2019;63(10):e01131-e1219.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1725_CR22","first-page":"ofz514","volume":"7","author":"JP Horcajada","year":"2020","unstructured":"Horcajada JP, Salata RA, \u00c1lvarez-Sala R, et al. A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP). Open Forum Infect Dis. 2020;7(1):ofz514.","journal-title":"Open Forum Infect Dis"},{"key":"1725_CR23","unstructured":"European Medicines Agency. Quofenix (delafloxacin): public assessment report. 2021. https:\/\/www.ema.europa.eu\/. Accessed 28 Apr 2022."},{"issue":"Suppl. 6","key":"1725_CR24","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","volume":"17","author":"M Woodhead","year":"2011","unstructured":"Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections\u2014full version. Clin Microbiol Infect. 2011;17(Suppl. 6):E1-59.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"1725_CR25","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-67.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1725_CR26","doi-asserted-by":"publisher","first-page":"e02609","DOI":"10.1128\/AAC.02609-16","volume":"61","author":"MA Pfaller","year":"2017","unstructured":"Pfaller MA, Sader HS, Rhomberg PR, et al. In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother. 2017;61(4):e02609-e2616.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1725_CR27","first-page":"131","volume":"2","author":"D Braeken","year":"2015","unstructured":"Braeken D, Franssen F, Sch\u00fctte H, et al. Increased severity and mortality of CAP in COPD: results from the German Competence Network, CAPNETZ. Chronic Obstr Pulm Dis. 2015;2(2):131\u201340.","journal-title":"Chronic Obstr Pulm Dis."},{"key":"1725_CR28","unstructured":"Breckenridge Pharmaceutical. Moxifloxacin hydrochloride: US prescribing information. 2021. https:\/\/dailymed.nlm.nih.gov\/. Accessed 28 Apr 2022."},{"issue":"1","key":"1725_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/phar.2050","volume":"38","author":"JC Cho","year":"2018","unstructured":"Cho JC, Crotty MP, White BP, et al. What is old is new again: delafloxacin, a modern fluoroquinolone. Pharmacotherapy. 2018;38(1):108\u201321.","journal-title":"Pharmacotherapy"},{"issue":"10","key":"1725_CR30","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s40261-020-00938-y","volume":"40","author":"TP Lodise","year":"2020","unstructured":"Lodise TP, Tillotson GS, Spargo A, et al. The role of delafloxacin in patients with community-acquired bacterial pneumonia in the outpatient setting: a budget impact model. Clin Drug Investig. 2020;40(10):961\u201371.","journal-title":"Clin Drug Investig"},{"issue":"Suppl. 3","key":"1725_CR31","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1093\/cid\/ciy1079","volume":"68","author":"PM Tulkens","year":"2019","unstructured":"Tulkens PM, Van Bambeke F, Zinner SH. Profile of a novel anionic fluoroquinolone\u2014delafloxacin. Clin Infect Dis. 2019;68(Suppl. 3):S213\u201322.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1725_CR32","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1128\/AAC.04813-14","volume":"59","author":"JS Litwin","year":"2015","unstructured":"Litwin JS, Benedict MS, Thorn MD, et al. A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization. Antimicrob Agents Chemother. 2015;59(6):3469\u201373.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1725_CR33","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1039\/C8PP00019K","volume":"17","author":"RS Dawe","year":"2018","unstructured":"Dawe RS, Ferguson J, Ibbotson S, et al. Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin. Photochem Photobiol Sci. 2018;17(6):773\u201380.","journal-title":"Photochem Photobiol Sci"},{"issue":"8","key":"1725_CR34","doi-asserted-by":"publisher","first-page":"e00339","DOI":"10.1128\/JCM.00339-18","volume":"56","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Flamm RK, McCurdy SP, et al. Delafloxacin in vitro broth microdilution and disk diffusion antimicrobial susceptibility testing guidelines: susceptibility breakpoint criteria and quality control ranges for an expanded-spectrum anionic fluoroquinolone. J Clin Microbiol. 2018;56(8):e00339-e418.","journal-title":"J Clin Microbiol"},{"issue":"Suppl. 1","key":"1725_CR35","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1093\/ofid\/ofab466.155","volume":"8","author":"D Shortridge","year":"2021","unstructured":"Shortridge D, Streit JM, Huband MD, et al. In vitro evaluation of delafloxacin activity against contemporary US isolates from community-acquired pneumonia and community-acquired lower respiratory tract infections: results from the SENTRY antimicrobial surveillance program (2014-2020) [abstract no. 155]. Open Forum Infect Dis. 2021;8(Suppl. 1):S93\u20134.","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl. 1","key":"1725_CR36","doi-asserted-by":"publisher","first-page":"S733","DOI":"10.1093\/ofid\/ofaa439.1644","volume":"7","author":"D Shortridge","year":"2020","unstructured":"Shortridge D, Streit JM, Huband MD, et al. Activity of delafloxacin against multi-drug-resistant fastidious respiratory pathogens from European medical centers (2014\u20132019) [abstract no. 1463]. Open Forum Infect Dis. 2020;7(Suppl. 1):S733.","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"1725_CR37","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1128\/AAC.00941-16","volume":"60","author":"RK Flamm","year":"2016","unstructured":"Flamm RK, Rhomberg PR, Huband MD, et al. In vitro activity of delafloxacin tested against isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 2016;60(10):6381\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 2","key":"1725_CR38","doi-asserted-by":"publisher","first-page":"S577","DOI":"10.1093\/ofid\/ofz360.1446","volume":"6","author":"D Shortridge","year":"2019","unstructured":"Shortridge D, Streit JM, Huband MD, et al. Delafloxacin activity against drug-resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US medical centers (2014\u20132018) [abstract no. 1582]. Open Forum Infect Dis. 2019;6(Suppl. 2):S577\u20138.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"1725_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.eimc.2020.09.016","volume":"40","author":"E Cercenado","year":"2022","unstructured":"Cercenado E, Loras C, Cobos A, et al. In vitro activity of delafloxacin against highly levofloxacin-resistant invasive isolates of Streptococcus pneumoniae. Enferm Infecc Microbiol Clin (Engl Ed). 2022;40(3):131\u20133.","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)."},{"key":"1725_CR40","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.2147\/IDR.S202789","volume":"12","author":"M Hipp","year":"2019","unstructured":"Hipp M, Burckhardt I. In vitro activity of newer antimicrobials against penicillin non-susceptible strains of Streptococcus pneumoniae. Infect Drug Resist. 2019;12:1889\u201393.","journal-title":"Infect Drug Resist."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01725-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01725-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01725-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:25:18Z","timestamp":1655771118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01725-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1725"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01725-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"28 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Arnold Lee, Yvette Lamb and Matt Shirley are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}